Immuneering (NASDAQ:IMRX) Upgraded to Hold at Wall Street Zen

Immuneering (NASDAQ:IMRX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

Other equities research analysts also recently issued reports about the company. Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Cantor Fitzgerald assumed coverage on Immuneering in a report on Wednesday. They issued an “overweight” rating and a $17.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. Finally, Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Immuneering in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $16.57.

Immuneering Stock Performance

Immuneering stock traded down $0.25 during trading on Friday, reaching $5.11. 827,746 shares of the company’s stock were exchanged, compared to its average volume of 1,456,130. Immuneering has a 52-week low of $2.90 and a 52-week high of $10.08. The firm has a market cap of $330.62 million, a price-to-earnings ratio of -4.37 and a beta of 0.41. The company’s 50-day moving average is $4.86 and its two-hundred day moving average is $5.18.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09. Analysts anticipate that Immuneering will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Immuneering

A number of institutional investors have recently modified their holdings of IMRX. Caitong International Asset Management Co. Ltd acquired a new position in Immuneering in the fourth quarter worth about $33,000. Levin Capital Strategies L.P. acquired a new position in shares of Immuneering in the 1st quarter worth approximately $53,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Immuneering in the 3rd quarter valued at approximately $70,000. SummitTX Capital L.P. acquired a new stake in shares of Immuneering during the 4th quarter valued at approximately $69,000. Finally, Ausdal Financial Partners Inc. bought a new position in Immuneering during the fourth quarter worth $72,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.